LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced product development highlights and financial results for the year ended December 31, 2006.
“The last year has been a pivotal and transitional time for BioSante,” said Stephen M. Simes, BioSante’s president and chief executive officer. “We achieved a number of significant milestones with both our hormone therapy products and CaP nanotechnology. Most notably, for our Elestrin™ transdermal estradiol gel product, we filed a new drug application (NDA) in February 2006. We subsequently received U.S. Food and Drug Administration (FDA) approval of Elestrin in December 2006 for the lowest estradiol dose ever approved by the FDA for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. Just prior to the FDA approval, we signed, in November 2006, an agreement with Bradley Pharmaceuticals, Inc. (NYSE:BDY) for the marketing of Elestrin in the U.S.
